What is Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market?
The Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market is a specialized sector within the broader pharmaceutical industry. It focuses on the development, production, and distribution of treatments for acute bacterial skin and skin structure infections. These infections, often referred to as ABSSSI, are severe, potentially life-threatening conditions that require immediate medical attention. The market encompasses a range of products, including antibiotics and other medications, designed to combat these infections. The global reach of this market signifies its importance, as ABSSSI is a universal health concern that affects individuals regardless of geographical location or socioeconomic status. The market's growth is driven by factors such as the increasing prevalence of ABSSSI, advancements in medical technology, and the ongoing efforts of pharmaceutical companies to develop more effective treatments.
Delafloxacin, Vancomycin, Ceftaroline Fosamil, Others in the Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market:
Delafloxacin, Vancomycin, and Ceftaroline Fosamil are among the key treatments available in the Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market. Delafloxacin is a novel fluoroquinolone antibiotic that has shown efficacy against a range of bacteria, including those resistant to other antibiotics. Vancomycin, a glycopeptide antibiotic, has been a mainstay of ABSSSI treatment for many years due to its broad-spectrum activity against Gram-positive bacteria. Ceftaroline Fosamil, a cephalosporin antibiotic, is notable for its activity against methicillin-resistant Staphylococcus aureus (MRSA), a common cause of ABSSSI. These treatments, along with others in the market, provide clinicians with a range of options to effectively manage ABSSSI, tailoring treatment to the specific needs of each patient.
Cellulitis, Abscess, Surgical Wounds, Traumatic Wound in the Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market:
The Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market plays a crucial role in managing a variety of conditions, including cellulitis, abscesses, surgical wounds, and traumatic wounds. Cellulitis, a common and potentially serious bacterial skin infection, can spread rapidly and requires prompt treatment. Abscesses, collections of pus that form within the body tissue, also require immediate medical attention. Surgical wounds and traumatic wounds, such as those sustained in accidents or during physical activities, are also prone to ABSSSI. The treatments available in this market are designed to effectively manage these conditions, preventing the spread of infection and promoting healing.
Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Outlook:
Looking at the market outlook, the global pharmaceutical market, which includes the Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market, is projected to reach a value of 1475 billion USD in 2022. This represents a compound annual growth rate (CAGR) of 5% over the next six years. In contrast, the chemical drug market is expected to grow from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. These figures underscore the significant growth potential of the pharmaceutical industry, driven by factors such as the increasing global disease burden, advancements in medical technology, and the ongoing efforts of pharmaceutical companies to develop more effective treatments.
| Report Metric | Details |
| Report Name | Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market |
| CAGR | 5% |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | Furiex Pharmaceuticals, Inc., GlaxoSmithKline plc, Melinta Therapeutics, Inc., Debiopharm International S.A., MerLion Pharmaceuticals Pte Ltd., Durata Therapeutics, Inc., Paratek Pharmaceuticals, Inc., Cempra, Inc., Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc., Allergan plc., AstraZeneca, Bayer AG, Macrolide Pharmaceuticals, Inc., Merck & Co, Inc., Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Zavante Therapeutics, Inc. |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
